TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03404908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Study: NCT00612742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: once daily transdermal testosterone gel, 300 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study: NCT04266509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 milligram (mg) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg provided as two 300 mg capsules.
Study: NCT02369666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LycoRed (code 40051) product
Description: Mixture of tomato lycopene and carotenoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LycoRed (code 40051) product
Description: Mixture of tomato lycopene and carotenoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Contains MCT oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains MCT oil.
Study: NCT04077294

Intervention type: OTHER
Intervention: Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring
Description: Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
Study: NCT02725697

Intervention type: OTHER
Intervention: TCM treatment
Study: NCT00376350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Massage
Description: light pressure massage of the low back.
Study: NCT04077294

Intervention type: OTHER
Intervention: Use of traditional perioperative cardiac risk stratification only
Description: Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
Study: NCT03980821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 taken orally
Study: NCT01739933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
Study: NCT04966728

Intervention type: DIAGNOSTIC_TEST
Intervention: conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
Description: conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
Study: NCT01275911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
Study: NCT00376350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: 5 minutes pulsed ultrasound

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulsed Ultrasound
Description: 5 minutes pulsed ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: 5 minutes pulsed ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: 5 minutes pulsed ultrasound
Study: NCT01529879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Abutment Connection implant
Description: New abutment connection implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain Tapered implant
Description: Nanotite Certain Tapered (standard abutment connection) implant
Study: NCT01570374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Description: 9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
Study: NCT01275911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
Study: NCT03022565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
Study: NCT01867021

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluvirin(TIVf)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agriflu (TIV)
Study: NCT02457910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies
Study: NCT03098199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300IU Gonal-F
Description: \<1.5 AMH group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150IU Menopur
Description: \<1.5 AMH group
Study: NCT02457910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies
Study: NCT03098199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225IU Gonal-F
Description: 1.6-2.5 AMH group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75IU Menopur
Description: 1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75IU Menopur
Description: 1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75IU Menopur
Description: 1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
Study: NCT02457910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO
Study: NCT03098199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150IU Gonal-F
Description: 2.6-6.9 AMH group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75IU Gonal-F
Description: \>7.0 AMH group
Study: NCT00286325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion of 1000 mg of rituximab on day 0 and day 14
Study: NCT01217736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren
Description: single dose, tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-27999
Description: single dose, tablet
Study: NCT01894737

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Seven days of one-legged knee immobilisation with placebo supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Description: Seven days of one-legged knee immobilisation with creatine supplementation.
Study: NCT01528683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Treatment with carbon ion radiotherapy using the rasterscanning technique
Study: NCT02699099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral administration of Vitamin A (1 dose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral administration of Vitamin A (1 dose)
Study: NCT02699099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Oral administration of Vitamin A (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Plasmodium falciparum malaria vaccine
Description: Intramuscular administration of SB257049 vaccine (4 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Plasmodium falciparum malaria vaccine
Description: Intramuscular administration of SB257049 vaccine (4 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Plasmodium falciparum malaria vaccine
Description: Intramuscular administration of SB257049 vaccine (4 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-Vac
Description: Subcutaneous injection of a combined measles and rubella vaccine (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-Vac
Description: Subcutaneous injection of a combined measles and rubella vaccine (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR-Vac
Description: Subcutaneous injection of a combined measles and rubella vaccine (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Intramuscular injection of a yellow fever (YF) vaccine (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Intramuscular injection of a yellow fever (YF) vaccine (1 dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril
Description: Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
Study: NCT02358863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Capecitabine
Description: Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Irinotecan
Description: Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
Study: NCT01842932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phloroglucin
Description: Premedication of colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide
Description: Premedication of colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Diagnostic examination of colon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Diagnostic examination of colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
Study: NCT02106078

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderated Discussion Board
Description: All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group.
Study: NCT01769560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MeFirst Tailored Intervention
Description: Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
Study: NCT01632280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks.
Study: NCT02740426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
Study: NCT00908310

Intervention type: DRUG
Group type: OTHER
Intervention: Omniscan
Description: OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
Study: NCT01178710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Study: NCT02292095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAPB group
Description: transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA group
Description: The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
Study: NCT02284607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: MHAA4549A single, intravenous dose administration, lower dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: MHAA4549A single, intravenous dose administration, higher dose level
Study: NCT04577664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total thyroidectomy
Description: a total thyroidectomy (TT) in which the entire gland is removed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subtotal thyroidectomy
Description: subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
Study: NCT02284607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MHAA4549A administration
Study: NCT02054429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
Study: NCT04216641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adapted food intervention
Description: Adapted food intervention
Study: NCT02457910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO
Study: NCT02412904

Intervention type: DRUG
Group type: OTHER
Intervention: rFSH
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days

Intervention type: DRUG
Group type: OTHER
Intervention: HMG
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Study: NCT05143723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Description: luteal phase support with gonadotropin-releasing hormone agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist
Description: luteal phase support with gonadotropin-releasing hormone agonist
Study: NCT03356977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Description: Applied BID
Study: NCT02362945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention group:
Description: Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
Study: NCT01768156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy
Study: NCT03091985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PersonalFit - Breast shield
Description: Subjects are to pump 15 min with the comparator device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PersonalFit - Breast shield
Description: Subjects are to pump 15 min with the comparator device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brownie - Breast shield
Description: Subjects are to pump 15 min with the investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brownie - Breast shield
Description: Subjects are to pump 15 min with the investigational device
Study: NCT02442791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byetta (Lilly, Exenatide)
Description: See description of Arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Human Albumin
Description: See description of Arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% Human Albumin
Description: See description of Arms
Study: NCT03981666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion.